Realty Income Corp vs Repligen Corporation Common Stock — how do they compare? Realty Income Corp trades at $55.65 (market cap $52.03B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Realty Income Corp is far larger — about 4.7× Repligen Corporation Common Stock's market cap, and Realty Income Corp pays a 5.92% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Realty Income Corp for 128 Days and Repligen Corporation Common Stock for 0 Days on average.
| O | RGEN | |
|---|---|---|
Market Cap | $52.03B | $11.14B |
Volume | 16,838,213 | 1,259,263 |
Sector | Real Estate | Health |
52-Week High | $67.56 | $194.57 |
52-Week Low | $53.35 | $102.87 |
Typical Hold Time | 128 Days | 0 Days |
Enterprise Value | $82.66B | $11.02B |
Dividend Yield | 5.92% | — |
Signals from Pluang's Aura AI — not financial advice
Realty Income (O) trades at $55.17, up 0.86% on the day, but remains in a bearish technical trend with recent earnings misses. The REIT maintains strong fundamentals with 92.56% gross margins and consistent dividend payments, though valuation metrics appear elevated with a P/E of 40.14. Recent news highlights the stock's sensitivity to rising Treasury yields, with the 10-year at 5.26% creating headwinds for REIT valuations.
The outlook remains cautious with analyst consensus at Buy (38%) but technical indicators bearish. Key opportunities include the 6% dividend yield and 136 consecutive dividend increases, while risks center on interest rate sensitivity and debt levels approaching 40% of assets. The $64.16 price target suggests 16% upside if fundamentals overcome rate pressures.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →